See more : American Electric Power Company, Inc. (0HEC.L) Income Statement Analysis – Financial Results
Complete financial analysis of Prelude Therapeutics Incorporated (PRLD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Prelude Therapeutics Incorporated, a leading company in the Biotechnology industry within the Healthcare sector.
- Mestek, Inc. (MCCK) Income Statement Analysis – Financial Results
- SFA Semicon Co., Ltd. (036540.KQ) Income Statement Analysis – Financial Results
- EG Acquisition Corp. (EGGF-UN) Income Statement Analysis – Financial Results
- Blackstone Loan Financing Limited (BGLP.L) Income Statement Analysis – Financial Results
- Eltek Ltd. (ELTK) Income Statement Analysis – Financial Results
Prelude Therapeutics Incorporated (PRLD)
About Prelude Therapeutics Incorporated
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.17M | 3.04M | 2.24M | 542.00K | 382.00K | 149.00K |
| Gross Profit | -1.17M | -3.04M | -2.24M | -542.00K | -382.00K | -149.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 103.39M | 92.89M | 86.78M | 48.18M | 24.28M | 12.62M |
| General & Administrative | 28.88M | 30.65M | 26.96M | 10.59M | 3.83M | 2.35M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 28.88M | 30.65M | 26.96M | 10.59M | 3.83M | 2.35M |
| Other Expenses | 0.00 | 8.10M | 2.04M | 1.83M | 539.00K | 295.00K |
| Operating Expenses | 132.28M | 123.54M | 113.74M | 58.76M | 28.11M | 14.98M |
| Cost & Expenses | 132.28M | 123.54M | 113.74M | 58.76M | 28.11M | 14.98M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.17M | 3.04M | 2.24M | 542.00K | 382.00K | 149.00K |
| EBITDA | -131.11M | -122.22M | -112.82M | -58.22M | -27.73M | -14.83M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -132.28M | -123.54M | -113.74M | -58.76M | -28.11M | -14.98M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 10.45M | 8.10M | 2.04M | 1.83M | 539.00K | 295.00K |
| Income Before Tax | -121.83M | -115.44M | -111.69M | -56.93M | -27.57M | -14.68M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -8.10M | -915.00K | 335.70K | 210.14K | 295.00K |
| Net Income | -121.83M | -107.34M | -110.78M | -56.93M | -27.57M | -14.68M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.02 | -2.27 | -2.33 | -1.30 | -0.85 | -0.46 |
| EPS Diluted | -2.02 | -2.27 | -2.33 | -1.30 | -0.85 | -0.46 |
| Weighted Avg Shares Out | 60.36M | 47.37M | 47.60M | 43.71M | 32.40M | 32.11M |
| Weighted Avg Shares Out (Dil) | 60.36M | 47.37M | 47.60M | 43.71M | 32.40M | 32.11M |
After Plunging -31.47% in 4 Weeks, Here's Why the Trend Might Reverse for Prelude Therapeutics (PRLD)
Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit
Down -39.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Prelude Therapeutics (PRLD)
Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium
Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024
Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
Source: https://incomestatements.info
Category: Stock Reports